Compare · AZN vs RANI
AZN vs RANI
Side-by-side comparison of AstraZeneca PLC (AZN) and Rani Therapeutics Holdings Inc. (RANI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and RANI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $263.07B, about 2743.2x RANI ($95.9M).
- Over the past year, AZN is down 9.9% and RANI is up 43.8% - RANI leads by 53.7 points.
- AZN has been more active in the news (11 items in the past 4 weeks vs 8 for RANI).
- AZN has more recent analyst coverage (25 ratings vs 13 for RANI).
- Company
- AstraZeneca PLC
- Rani Therapeutics Holdings Inc.
- Price
- $169.61-1.03%
- $0.78-5.46%
- Market cap
- $263.07B
- $95.9M
- 1M return
- -7.79%
- +1.67%
- 1Y return
- -9.92%
- +43.83%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2021
- News (4w)
- 11
- 8
- Recent ratings
- 25
- 13
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-103, a glucagon-like peptide-1 mimetic to treat type 2 diabetes; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers
- AstraZeneca results: H1 and Q2 2026
- SEC Form 6-K filed by AstraZeneca PLC
- Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest RANI
- Director Imran Mir A bought $24,840 worth of shares (36,000 units at $0.69), increasing direct ownership by 2% to 2,119,334 units (SEC Form 4)
- Chief Technical Officer Javadi Alireza sold $301 worth of shares (386 units at $0.78) and covered exercise/tax liability with 309 shares, decreasing direct ownership by 7% to 9,380 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Imran Talat bought $25,193 worth of shares (35,000 units at $0.72), increasing direct ownership by 8% to 469,736 units (SEC Form 4)
- Chief Executive Officer Imran Talat sold $11,300 worth of shares (8,014 units at $1.41) and covered exercise/tax liability with 52,001 shares, decreasing direct ownership by 12% to 434,736 units (SEC Form 4) (withholding obligation)
- SEC Form 4 filed by Chief Financial Officer Maestas Nicholas
- Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form S-8 filed by Rani Therapeutics Holdings Inc.
- Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing
- Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates
- SEC Form 3 filed by new insider Maestas Nicholas